Приказ основних података о дисертацији
Beta estrogen receptor kao prognostički faktor u adenokarcinomu pluća
Beta-estrogen receptor as a prognostic factor in lung adenocarcinoma
dc.contributor.advisor | Perin, Branislav | |
dc.contributor.advisor | Kosjerina, Zdravko | |
dc.contributor.other | Sečen, Nevena | |
dc.contributor.other | Stanić, Jelena | |
dc.contributor.other | Panjković, Milana | |
dc.contributor.other | Đurić, Dejan | |
dc.contributor.other | Andrijević, Ilija | |
dc.creator | Lalić, Nensi | |
dc.date.accessioned | 2021-03-18T09:47:15Z | |
dc.date.available | 2021-03-18T09:47:15Z | |
dc.date.issued | 2014-05-20 | |
dc.identifier.uri | https://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija139229925522741.pdf?controlNumber=(BISIS)85453&fileName=139229925522741.pdf&id=1345&source=NaRDuS&language=sr | sr |
dc.identifier.uri | https://www.cris.uns.ac.rs/record.jsf?recordId=85453&source=NaRDuS&language=sr | sr |
dc.identifier.uri | https://www.cris.uns.ac.rs/DownloadFileServlet/IzvestajKomisije139221311990560.pdf?controlNumber=(BISIS)85453&fileName=139221311990560.pdf&id=1335&source=NaRDuS&language=sr | sr |
dc.identifier.uri | /DownloadFileServlet/IzvestajKomisije139221311990560.pdf?controlNumber=(BISIS)85453&fileName=139221311990560.pdf&id=1335 | |
dc.identifier.uri | https://nardus.mpn.gov.rs/handle/123456789/18102 | |
dc.description.abstract | Prema statističkim podacima Svetske Zdravstvene Organizacije, karcinom bronha se po učestalosti kod muškaraca nalazi na prvom mestu, a kod žena na drugom mestu, odmah posle karcinoma dojke. Posmatranjem trenda incidence karcinoma bronha u dužem vremenskom periodu u odnosu na pol, u većini evropskih zemalja se beleži pad incidence kod muškaraca uz porast incidence kod žena. Povećanje incidence u ženskoj populaciji na prvom mestu povezuje se sa sve rasprostranjenijom navikom pušenja u žena širom sveta. Kao jedan od mogućih faktora koji utiču na uzlazni trend pojave karcinoma kod žena navodi se i hormonalni status (estrogeni status) tim pre što je procenat pušača u ženskoj populaciji obolelih od karcinoma bronha još uvek manji nego u muškoj populaciji. Estrogeni se mogu ponašati kao promoteri u procesu kancerogeneze, preko receptor posredovanih mehanizama, preko kojih dovode do ćelijske proliferacije. Postoje dve vrste estrogenih receptora (Alfa i Beta estrogeni receptori-ER). Imunohistohemijski dokazano je uglavnom negativno prisustvo Alfa-ER (ERα) u zdravom tkivu pluća kao i u tkivu karcinoma pluća, dok je Beta-ER (ERβ) u dosadašnjim istraživanjima bio signifikantno povišen u tkivu tumora pluća u odnosu na zdravo tkivo pluća. Ekspresija ERβ u odnosu na ekspresiju ERα je mnogo više prisutna u karcinomu bronha i kreće se od 9%-98%. U našem radu ekspresija ERβ iznosila je 39,0%. Ciljevi ove doktorske disertacije bili su: određivanje terapijskog odgovora kod pacijenata obolelih od adenokarcinoma pluća prema prisutnosti beta estrogenog receptora u tkivu tumora, utvrđivanje preživljavanje pacijenata sa adenokarcinomom pluća prema prisutnosti beta estrogenog receptora (ERβ) u tkivu tumora, utvrđivanje razlike u preživljavanju i terapijskom odgovoru po polu, a prema estrogen beta receptorskom statusu i na kraju da li beta estrogen receptor može biti prognostički faktor za pacijente sa adenokarcinomo pluća. Bolji terapijski odgovor i duži period do progresije bolesti postoji kod žena sa pozitivnim beta estrogenim receptorskim statusom. Kod muškaraca receptorski status nema uticaja na terapijski odgovor i period do progresije bolesti. Žene sa pozitivnim beta estrogenim receptorskim statusom imale su statistički značajno bolje preživljavanje nego žene i muškarci sa negativnim beta estrogenim receptorskim statusom, odnosno muškarci sa pozitivnim receptorskim statusom. Kod pacijenata sa pozitivnim beta estrogen receptorskim statusom petogodišnje preživljavanje u IA i IB stadijumu bolesti je statistički značajno bolje. Kod pacijenata sa pozitivnim beta estrogen receptorskim statusom jednogodišnje preživljavanje u IIIb i IV stadijumu bolesti je statistički značajno bolje. Period do progresije bolesti je duži za žene sa estrogen beta pozitivnim receptorskim statusom u odnosu na žene sa estrogen beta negativnim receptorskim statusom i muškarce bez obzira na receptorski status. Beta estrogen receptor je nezavisni prognostčki faktor za pacijente sa adenokarcinomom pluća zajedno sa stadijumom bolesti i vrstom primenjene terapije. Dobijeni rezultati navode nas ma zaključak da je hormonski receptorski staus sigurno jedan od mnogobrojnih dosada ispitivanih faktora u kancerogenezi karcinoma bronha i može biti prognostički faktor za karcinom bronha kao i potencijalni faktor u multimodalitetnom lečenju (primena hormonske terapije - antiestrogeni) ovog malignog oboljenja. | sr |
dc.description.abstract | According to the statistical reports of the World Health ,Organisation, lung cancer takes the first and second leading position among the most common malignancies in men and women (following breast cancer) respectively. Reviewing the incidence of lung cancer related to patients sex over a longer time period, its decrease in males and increase in females has been registered in most European countries. The greater lung cancer incidence in the female population has been primarily correlated to the increasingly present smoking habit among females all over the world. The hormonal (estrogen) status has been reported as another ssiblefactor contributing to the increasing incidence of lung cancer in females, particularly due to the fact that still a fact that still a lower percentage of smoking women is affected by lung cancer than smoking men. Estrogens may behave aspromoters in the process of carcinogenesis, via receptormediated m(ER?), and beta (ER?). It has beenechanisms, leading to cell proliferationThere are two types of estrogen receptors (ER)-alphaimmunohistochemically established that the presenceER? was predominantly negative in both the healthy and cancerous lung tissue, unlike the presence of ER?, which was significantly increased in the lung cancer tissue compared to the healthy lung tissue. ER? expression is excessively higher in lung cancer (ranging from 9 percents 98 percents) than ER? expression. In our study, ER? expression was 39.0 percents. The objectives of this PhD study were to establish the treatment response of lung adenocarcinoma patients depending on the presencER? in the tumor tissue; the survival of patients with lung adenocarcinoma depending on the presence of ER? in the tumor tissue; the treatment response and survival differences between the sexes depending on the ER?e status, and finally whether the ER? status may be a prognostic factor in these patients. A better treatment response and a longer remission has been registered in females with the positive ER? status. In males, the ER status has been found irrelevant for either the treatment response, or the period until the disease progression. The females with the positive ER? status had a significantly better survival than both females and males with the negative ER? status, or males with the positive ER? status. Stage IA and IB lung adenocarcinoma patients with the positive ER? status had a significantly better five-year survival. Stage IIIB and IV patients with the positive ER? status had a significantly better one-year survival. The period until progression of the disease was longer in ER? positive females than in either ER? negative females, or in males regardless their ER status. The ER? status has been established an dependent prognostic factor for patients with lung adenocarcinoma , in addition to the disease stage, and applied treatment modality. The obtained results suggest a conclusion that the hormonal receptor status is oubtlessly one of many factors in lung cancer carcinogenesis which have been investigated so far, and may be establishe as a prognostic factor in lung cancer, as well as a potential factor in multi modal (hormonal therapy-anti estrogen) treatment of this malignancy. | en |
dc.language | sr (latin script) | |
dc.publisher | Универзитет у Новом Саду, Медицински факултет | sr |
dc.rights | openAccess | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.source | Универзитет у Новом Саду | sr |
dc.subject | adenokarcinom | sr |
dc.subject | Adenocarcinoma | en |
dc.subject | neoplazme pluća | sr |
dc.subject | estrogenski receptor beta | sr |
dc.subject | prognoza | sr |
dc.subject | preživljavanje | sr |
dc.subject | polni faktori | sr |
dc.subject | karcinogeneza | sr |
dc.subject | Lung Neoplasms | en |
dc.subject | Estrogen Receptor beta | en |
dc.subject | Prognosis | en |
dc.subject | Survival | en |
dc.subject | Sex Factors | en |
dc.subject | Carcinogenesis | en |
dc.title | Beta estrogen receptor kao prognostički faktor u adenokarcinomu pluća | sr |
dc.title.alternative | Beta-estrogen receptor as a prognostic factor in lung adenocarcinoma | en |
dc.type | Doktorska disertacija | sr |
dc.rights.license | BY-NC | |
dcterms.abstract | Перин, Бранислав; Косјерина, Здравко; Сечен, Невена; Пањковић, Милана; Ђурић, Дејан; Aндријевић, Илија; Станић, Јелена; Лалић, Ненси; Бета естроген рецептор као прогностички фактор у аденокарциному плућа; Бета естроген рецептор као прогностички фактор у аденокарциному плућа; | |
dc.identifier.fulltext | https://nardus.mpn.gov.rs/bitstream/id/70058/Disertacija.pdf | |
dc.identifier.fulltext | https://nardus.mpn.gov.rs/bitstream/id/70059/IzvestajKomisije.pdf | |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_nardus_18102 |